Investor · 1 deal
Every published round LGT Crestone took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Series D+ | Aug 2025 | $49m | Participant | Startup Daily (23 Dec 2025), SmartCompany (23 Dec 2025), Startup Daily (14 Oct 2025), Cut Through Venture, Startup Daily (29 Aug 2025), SmartCompany (29 Aug 2025), Startup Daily (26 Aug 2025), Business News Australia |
Companies LGT Crestone has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Vaxxas | Biotech/MedTech company | Aug 2025, Series D+ | 1 | 0 |
This is a stake in the fund itself, money that the fund's manager invests, not a stake in the fund manager.
Companies LGT Crestone has backed that another company then bought. An exit for the holding, not a deal LGT Crestone did.
| Name | Role | Sources |
|---|---|---|
| Michael Chisholm | CEO | Main Sequence |
Stories naming LGT Crestone. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Deep tech venture firm Main Sequence has reached an initial A$450 million close on its third fund, pushing money under management past A$1 billion; Hostplus, Temasek and CSIRO are among the backers.
Also SmartCompany·SmartCompany·Startup Daily·SmartCompany·Startup Daily·Startup Daily·TechCrunch Australia·@AuManufacturing